These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 35993369)

  • 1. Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis.
    Torres S; Ortiz C; Bachtler N; Gu W; Grünewald LD; Kraus N; Schierwagen R; Hieber C; Meier C; Tyc O; Joseph Brol M; Uschner FE; Nijmeijer B; Welsch C; Berres ML; Garcia-Ruiz C; Fernandez-Checa JC; Trautwein C; Vogl TJ; Zeuzem S; Trebicka J; Klein S
    Hepatology; 2023 Apr; 77(4):1228-1240. PubMed ID: 35993369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis.
    Klein S; Rick J; Lehmann J; Schierwagen R; Schierwagen IG; Verbeke L; Hittatiya K; Uschner FE; Manekeller S; Strassburg CP; Wagner KU; Sayeski PP; Wolf D; Laleman W; Sauerbruch T; Trebicka J
    Gut; 2017 Jan; 66(1):145-155. PubMed ID: 26385087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosis.
    Granzow M; Schierwagen R; Klein S; Kowallick B; Huss S; Linhart M; Mazar IG; Görtzen J; Vogt A; Schildberg FA; Gonzalez-Carmona MA; Wojtalla A; Krämer B; Nattermann J; Siegmund SV; Werner N; Fürst DO; Laleman W; Knolle P; Shah VH; Sauerbruch T; Trebicka J
    Hepatology; 2014 Jul; 60(1):334-48. PubMed ID: 24619965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pilot study of the antifibrotic effects of the multikinase inhibitor pacritinib in a mouse model of liver fibrosis.
    Al-Fayoumi S; Hashiguchi T; Shirakata Y; Mascarenhas J; Singer JW
    J Exp Pharmacol; 2018; 10():9-17. PubMed ID: 29785143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nrf2 induces lipocyte phenotype via a SOCS3-dependent negative feedback loop on JAK2/STAT3 signaling in hepatic stellate cells.
    Lu C; Xu W; Shao J; Zhang F; Chen A; Zheng S
    Int Immunopharmacol; 2017 Aug; 49():203-211. PubMed ID: 28601022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JQ-1 ameliorates schistosomiasis liver fibrosis by suppressing JAK2 and STAT3 activation.
    Ding H; Yang X; Tian J; Wang X; Ji Y; El-Ashram S; Ren C; Shen J; Liu M
    Biomed Pharmacother; 2021 Dec; 144():112281. PubMed ID: 34624676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The JAK2/STAT3 inhibitor pacritinib effectively inhibits patient-derived GBM brain tumor initiating cells in vitro and when used in combination with temozolomide increases survival in an orthotopic xenograft model.
    Jensen KV; Cseh O; Aman A; Weiss S; Luchman HA
    PLoS One; 2017; 12(12):e0189670. PubMed ID: 29253028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ruxolitinib suppresses liver fibrosis progression and accelerates fibrosis reversal via selectively targeting Janus kinase 1/2.
    Song Z; Liu X; Zhang W; Luo Y; Xiao H; Liu Y; Dai G; Hong J; Li A
    J Transl Med; 2022 Apr; 20(1):157. PubMed ID: 35382859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Panax notoginseng saponins ameliorates experimental hepatic fibrosis and hepatic stellate cell proliferation by inhibiting the Jak2/ Stat3 pathways.
    Hui J; Gao J; Wang Y; Zhang J; Han Y; Wei L; Liu Xiaochuang ; Wu J
    J Tradit Chin Med; 2016 Apr; 36(2):217-24. PubMed ID: 27400477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic effect of pacritinib with erlotinib on JAK2-mediated resistance in epidermal gowth factor receptor mutation-positive non-small cell lung Cancer.
    Ochi N; Isozaki H; Takeyama M; Singer JW; Yamane H; Honda Y; Kiura K; Takigawa N
    Exp Cell Res; 2016 Jun; 344(2):194-200. PubMed ID: 27180268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation.
    Bates J; Vijayakumar A; Ghoshal S; Marchand B; Yi S; Kornyeyev D; Zagorska A; Hollenback D; Walker K; Liu K; Pendem S; Newstrom D; Brockett R; Mikaelian I; Kusam S; Ramirez R; Lopez D; Li L; Fuchs BC; Breckenridge DG
    J Hepatol; 2020 Oct; 73(4):896-905. PubMed ID: 32376414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metformin attenuates motility, contraction, and fibrogenic response of hepatic stellate cells
    Li Z; Ding Q; Ling LP; Wu Y; Meng DX; Li X; Zhang CQ
    World J Gastroenterol; 2018 Feb; 24(7):819-832. PubMed ID: 29467552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin ameliorates activation of hepatic stellate cells and hepatic fibrosis by succinate and GPR91 inhibition.
    Nguyen G; Park SY; Le CT; Park WS; Choi DH; Cho EH
    Biochem Biophys Res Commun; 2018 Jan; 495(4):2649-2656. PubMed ID: 29278707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physalin D attenuates hepatic stellate cell activation and liver fibrosis by blocking TGF-β/Smad and YAP signaling.
    Xiang D; Zou J; Zhu X; Chen X; Luo J; Kong L; Zhang H
    Phytomedicine; 2020 Nov; 78():153294. PubMed ID: 32771890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis.
    Witek RP; Stone WC; Karaca FG; Syn WK; Pereira TA; Agboola KM; Omenetti A; Jung Y; Teaberry V; Choi SS; Guy CD; Pollard J; Charlton P; Diehl AM
    Hepatology; 2009 Nov; 50(5):1421-30. PubMed ID: 19676126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatoprotective effect of genistein against dimethylnitrosamine-induced liver fibrosis in rats by regulating macrophage functional properties and inhibiting the JAK2/STAT3/SOCS3 signaling pathway.
    Xu Y; Zhang D; Yang H; Liu Y; Zhang L; Zhang C; Chen G; Hu Y; Chen J; Zhang H; Mu Y; Liu P; Liu W
    Front Biosci (Landmark Ed); 2021 Dec; 26(12):1572-1584. PubMed ID: 34994171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel role of glutathione S-transferase A3 in inhibiting hepatic stellate cell activation and rat hepatic fibrosis.
    Chen H; Gan Q; Yang C; Peng X; Qin J; Qiu S; Jiang Y; Tu S; He Y; Li S; Yang H; Tao L; Peng Y
    J Transl Med; 2019 Aug; 17(1):280. PubMed ID: 31443720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CPEB4 Increases Expression of PFKFB3 to Induce Glycolysis and Activate Mouse and Human Hepatic Stellate Cells, Promoting Liver Fibrosis.
    Mejias M; Gallego J; Naranjo-Suarez S; Ramirez M; Pell N; Manzano A; Suñer C; Bartrons R; Mendez R; Fernandez M
    Gastroenterology; 2020 Jul; 159(1):273-288. PubMed ID: 32169429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of miR-188-5p alleviates hepatic fibrosis by significantly reducing the activation and proliferation of HSCs through PTEN/PI3K/AKT pathway.
    Riaz F; Chen Q; Lu K; Osoro EK; Wu L; Feng L; Zhao R; Yang L; Zhou Y; He Y; Zhu L; Du X; Sadiq M; Yang X; Li D
    J Cell Mol Med; 2021 Apr; 25(8):4073-4087. PubMed ID: 33689215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gα
    Kim KM; Han CY; Kim JY; Cho SS; Kim YS; Koo JH; Lee JM; Lim SC; Kang KW; Kim JS; Hwang SJ; Ki SH; Kim SG
    J Hepatol; 2018 Mar; 68(3):493-504. PubMed ID: 29080810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.